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Abstract
Chemokines play critical roles in HIV-1 infection, serving both to modulate viral replication and to recruit target cells to sites of
infection. Interferon--inducible protein 10 (IP-10/CXCL10) is a C-X-C chemokine that acts specifically upon activated T cells and
macrophages and attracts T cells into the cerebrospinal fluid (CSF) in HIV-associated neurological disease. We now demonstrate that IP-10
stimulates HIV-1 replication in monocyte-derived macrophages and peripheral blood lymphocytes. We further demonstrate that neutral-
ization of endogenous IP-10 or blocking the function of its receptor, CXCR3, reduces HIV-1 replication in these same cells. Therefore,
blocking the interaction between IP-10 and CXCR3 represents a possible new target for anti-retroviral therapy.
© 2003 Elsevier Science (USA). All rights reserved.
Introduction
The immune response to HIV-1 plays an important role
in the development and progression of disease in infected
individuals. HIV-1-induced cytokines exert protective and
pathogenic effects on many cellular targets (Garzino-Demo
et al., 2000; Hogan and Hammer, 2001; Kinter et al., 2000).
Chemokines, in particular, have been demonstrated to play
a central role in the immune response to HIV-1 infection
(Garzino-Demo et al., 2000). Chemokines are a subset of
the cytokine family that attracts and activates leukocytes via
interactions with seven-transmembrane domain G protein-
coupled receptors (GPCR) (Zlotnik et al., 1999). In the past
few years, it has been shown that the ligands of the C-C
chemokine receptor CCR5, MIP-1/CCL3, MIP-1/CCL4,
and RANTES/CCL5 suppress HIV replication (Cocchi et
al., 1995; Coffey et al., 1997), although under some circum-
stances these same chemokines can actually enhance HIV-1
replication (Dolei et al., 1998; Kelly et al., 1998; Kinter et
al., 1998; Schmidtmayerova et al., 1996). Isolates of HIV-1
that utilize CCR5 as a coreceptor (R5 HIV) can infect both
monocyte-derived macrophages (MDM) and CD4 T lym-
phocytes (Alkhatib et al., 1996; Choe et al., 1996; Deng et
al., 1996; Doranz et al., 1996; Dragic et al., 1996). It has
been demonstrated that individuals having mutations in both
alleles for CCR5 are highly resistant to HIV-1 infection and
that individuals that are heterozygous for the CCR5 32
mutation have a delayed clinical course following HIV-1
infection (Dean et al., 1996; Liu et al., 1996; Samson et al.,
1996; Smith et al., 1997).
During the course of infection, HIV-1 expands its corecep-
tor usage to include the C-X-C chemokine receptor CXCR4, as
well as other chemokine receptors. CXCR4-using strains of
HIV-1 (X4 HIV) are associated with disease progression, de-
cline in peripheral CD4 T lymphocyte levels, and the onset of
the clinical symptoms of AIDS (Connor et al., 1997).
SDF-1/CXCL12, the ligand for CXCR4, has also been
shown to inhibit HIV-1 replication (Bleul et al., 1996;
Marechal et al., 1999; Oberlin et al., 1996), although under
some conditions, it also can stimulate HIV-1 replication
(Bleul et al., 1996; Marechal et al., 1999; Oberlin et al.,
1996).
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The interferon--inducible protein 10 (IP-10/CXCL10)
is a C-X-C chemokine that has been shown to attract acti-
vated T lymphocytes and monocytes (Luster and Leder,
1993; Luster et al., 1985; Taub et al., 1993, 1996). IP-10
exerts its actions by binding to the chemokine receptor
CXCR3, which also serves as the receptor for monokine
induced by -interferon (MIG/CXCL9), and interferon-in-
ducible T cell alpha chemoattractant (I-TAC/CXCL11)
(Loetscher et al., 1996). The expression and function of
IP-10, MIG, and I-TAC are differentially regulated, and
they are believed to serve nonredundant functions in vivo
(Farber, 1997).
Although CXCR3 is not known to function as a core-
ceptor for HIV (Zlotnik et al., 1999), the expression of
CXCR3 and its ligands is induced in the context of HIV
infection. Increased levels of IP-10 have been detected in
the plasma of HIV-1-infected individuals compared with
controls, and persistently elevated IP-10 has been correlated
with immunological treatment failure following HAART
(Stylianou et al., 2000). IP-10 mRNA has also been shown
to be elevated within alveolar macrophages of HIV-sero-
positive individuals (Buhl et al., 1993), and IP-10 is induced
following infection of MDM and peripheral blood mono-
nuclear cells (PBMC) (Poluektova et al., 2001; Wetzel et
al., 2002). In addition, IP-10 and CXCR3 have been de-
tected in the brains of SIV-infected macaques with enceph-
alitis and of HIV-1-infected individuals (Sanders et al.,
1998; Sasseville et al., 1996; Westmoreland et al., 1998).
IP-10 has also been shown to be present in the cerebrospinal
fluid (CSF) of HIV-1-infected individuals and acts as the
major T cell chemotactic factor in the CSF (Kolb et al.,
1999). IP-10 is produced by astrocytes treated with HIV-1
Tat and gp120 (Asensio et al., 2001; Kutsch et al., 2000).
We now demonstrate that IP-10 stimulates HIV-1 replica-
tion in MDM and peripheral blood lymphocytes (PBL) and
that neutralization of endogenous IP-10 or blocking CXCR3
reduces HIV-1 replication in these same cells. Inhibition of
IP-10 function may therefore represent a new target for
anti-retroviral therapy.
Results
IP-10 stimulates HIV-1 replication in MDM and PBL
Many previous reports have indicated that certain cyto-
kines, including members of the chemokine family, can
affect the ability of HIV-1 to replicate within target cells
(Garzino-Demo et al., 2000; Hogan and Hammer, 2001;
Kinter et al., 2000). The chemokines RANTES, MIP-1,
MIP-1, and SDF-1 are major HIV regulatory factors that
suppress HIV replication under most circumstances and
enhance replication under other select circumstances (Bleul
et al., 1996; Cocchi et al., 1995; Kinter et al., 1998; Oberlin
et al., 1996; Schmidtmayerova et al., 1996). We have also
demonstrated that the C-X-C chemokines GRO- and IL-8
participate in autocrine loops that enhance HIV-1 replica-
tion (Lane et al., 2001a,b). Since the ligands for CXCR1,
CXCR2, and CXCR4 affect HIV-1 replication in MDM and
PBL, we investigated the effect that CXCR3 ligands have
on HIV-1 infection in primary human lymphocytes and
macrophages.
Cultures of PBL and MDM were collected from healthy
seronegative volunteers and infected with HIV-1. Recom-
binant human IP-10 was added prior to infection and re-
plenished throughout the period of culture. Viral replication
in MDM infected with the CCR5-using isolate HIV-1BaL
was assessed by measuring the amount of RT activity
present in the cellular supernatants at several points in time
after infection (Fig. 1A). In experiments with 10 different
donors’ cells, IP-10 stimulated HIV-1BaL replication 8.2-
fold on average (range: 1.5- to 29-fold). This increase was
found to be statistically significant (P  0.03), as deter-
mined by the Student’s t test. IP-10 was also found to
stimulate the replication of the X4 isolate HIV-1BRU in PBL
(Fig. 1B). Doses of IP-10 in the range of 5 to 125 ng/ml
stimulated replication, with a mean increase of 1.4-fold for
5 ng/ml, 2.3-fold for 25 ng/ml, and 2.8-fold for 125 ng/ml,
in five independent experiments. The increases with 25 and
125 ng/ml were statistically significant with P values of
0.033 and 0.01 by the Student’s t test. IP-10 also stimu-
lated the replication of several other isolates of HIV in PBL,
including HIV-1BaL (R5), HIV-1IIIB (X4), and HIV-2CBL-20
(X4) (data not shown).
The CXCR3 ligands MIG and I-TAC also had a stimu-
latory effect on HIV-1BRU replication in PBL (Figs. 1C and
1D). In five independent experiments, mean increases of
2.4-fold for 5 ng/ml, 2.4-fold for 25 ng/ml, and 2.0-fold for
125 ng/ml were observed with MIG. I-TAC stimulated
HIV-1 replication 2.5-fold at 5 ng/ml, 2.5-fold at 25 ng/ml,
and 3.1-fold at 125 ng/ml. All of these increases were found
to be statistically significant (P  0.05) by the Student’s t
test. No difference in cellular viability was observed fol-
lowing treatment of MDM or PBL with IP-10 (Table 1), or
with MIG or I-TAC (data not shown). These data indicate
that the effect of these chemokines upon HIV-1 replication
is principally via an effect upon the process of viral repli-
cation and not an effect upon the activation, proliferation, or
viability of the cells themselves.
IP-10 does not activate HIV-1 gene expression
Many cytokines are known to stimulate HIV-1 replica-
tion via effects on HIV-1 gene expression (Duh et al., 1989;
Folks et al., 1987, 1989). For this reason, we employed a
number of models to determine whether IP-10, similar to
TNF- and the phorbol ester PMA, could be shown to
stimulate HIV-1 long terminal repeat (LTR)-mediated gene
expression. We first looked at two commonly used, chron-
ically infected cell lines in which HIV-1 can be induced
from latency by a number of factors, including PMA. The
cell line U1 is a derivative of the U937 monocytic cell line
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containing two integrated copies of provirus with tat muta-
tions that maintain the virus in a state of postintegration
latency (Emiliani et al., 1998). U1 cells have little baseline
production of virus, but viral replication can be induced by
PMA and inflammatory cytokines, such as TNF- (Folks et
al., 1987). Flow cytometric analysis of U1 cells revealed
that these cells express CXCR3 on their cell surface (Fig.
2A). We found that, in contrast to treatment with PMA,
treatment with IP-10 was unable to induce HIV-1 from
latency in U1 cells (Fig. 2B). Similarly, while HIV replica-
tion can be induced in the chronically infected T cell line
ACH2 by PMA and cytokines (Duh et al., 1989; Folks et al.,
1989), we found that IP-10 had no effect (data not shown).
Thus, unlike other cytokines, such as TNF- and IL-1 (Duh
et al., 1989), IP-10 does not exert its stimulatory effect on
HIV-1 by enhancing LTR-mediated gene expression in
these latent models of HIV-1 infection.
To determine whether IP-10 could induce gene expres-
sion in a model in which the Tat-TAR axis had not been
disrupted, as it is in both the U1 and the ACH2 cell lines
(Emiliani et al., 1996, 1998), we next studied the effect of
IP-10 in Jurkat T cells. Jurkat cells previously have been
shown to express CXCR3 (Loetscher et al., 1996). Jurkat
cells were transfected with a CAT reporter gene under the
control of the HIV-1 LTR (HIV-1 LTR-CAT) with or with-
out a plasmid containing HIV-1 Tat under the control of the
RSV promoter (RSV-Tat). After 16 h, Jurkat cells were
treated with IP-10, treated with PMA as a positive control,
Fig. 1. The CXCR3 ligands stimulate HIV-1 replication. (A) MDM were treated with IP-10 (25 ng/ml) every 3 days, beginning 1 day before infection with
the CCR5-using isolate HIV-1BaL. Supernatants were analyzed for RT activity 7 and 10 days after infection. Data shown represent the average value of RT
activity in triplicate wells, and this experiment is representative of 10 independent experiments. IP-10 (B), MIG (C), and I-TAC (D) stimulate replication of
the CXCR4-using isolate HIV-1BRU in PBL. PBL were treated with chemokines at a dose of 5, 25, or 125 ng/ml every 3 days beginning 1 day before infection.
Viral replication was assessed on days 3, 6, and 9 by RT assay. Data shown represent the average value of RT activity in triplicate wells, and this experiment
is representative of five independent experiments.
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or subjected to no further treatment as a negative control.
LTR-directed gene expression in the Jurkat cells was in-
duced by both PMA and Tat, but IP-10 did not increase
CAT activity in either the presence or the absence of HIV-1
Tat (Fig. 3A). We also examined the effect of IP-10 on 1G5
cells, a clonal cell line derived from Jurkat T cells that is
stably transfected with the luciferase gene under the control
of the HIV-1 LTR (HIV-1 LTR-luc). 1G5 cells have low
basal luciferase activity, which can be induced 10- to 1000-
fold by Tat and T cell activation signals (Aguilar-Cordova
et al., 1994). Luciferase activity was stimulated by treatment
of 1G5 cells with TNF- or PMA, but not by treatment with
IP-10 (Fig. 3B). Taken together, these experiments indicate
that IP-10 does not stimulate HIV-1 LTR-mediated gene
expression in the Jurkat T cell line.
To address whether IP-10 might affect HIV-1 gene ex-
pression in primary cells, we transiently transfected PBL
with HIV-1 LTR-luc with or without RSV-Tat by an elec-
troporation method. This method was determined to be
effective for transfecting PBL, as luciferase activity was
induced 100- to 1000-fold above background by PMA or
HIV-1 Tat, which served as positive controls (Table 2).
Following electroporation, PBL were separated into indi-
vidual wells and treated with IP-10, PMA, or no treatment
(Table 2). IP-10 did not have a consistent stimulatory effect
on gene expression from the HIV-1 LTR in the absence of
Tat and actually reduced Tat-mediated LTR activity 2.0-
and 11.4-fold in the two donors (Table 2), making it un-
likely that gene expression is responsible for the induction
of HIV-1 replication seen in PBL. Taken together, these
experiments suggest that the mechanism by which IP-10
stimulates HIV-1 replication is distinct from the mecha-
nisms by which other cellular activation signals, such as
TNF- and PMA, have been shown to act.
IP-10 increases the accumulation of HIV-1 DNA in
infected cells
To determine the step in the HIV-1 life cycle at which
IP-10 acts, we next investigated the accumulation of the
products of reverse transcription (RT) in cells infected with
HIV-1 for less than 24 h. Primers to the U3 region and
primer binding site (PBS) of the HIV-1 genome, and a probe
recognizing the R/U5 region, were used in real-time quan-
titative polymerase chain reaction (PCR) reactions. This
primer pair detects viral DNA sequences that are present
after the second-strand transfer (Zack et al., 1990). Thus,
this method allows us to assess whether the chemokine
effect on HIV-1 replication takes place before the stage of
viral transcription.
An increase in viral DNA was observed in MDM or PBL
that had been pretreated with IP-10 for 24 h (Fig. 4). A
similar increase was seen following treatment with GRO-,
which we have previously shown to also stimulate HIV-1
replication (Lane et al., 2001b). As we have observed pre-
viously with the effect of chemokine treatment on viral
replication as determined by RT activity (Lane et al.,
2001a,b), there was a good deal of donor-to-donor variabil-
ity in the effect of IP-10 on the increase in the amount of
viral DNA in infected cells. The range of increase in viral
DNA following chemokine pretreatment was between 0.22-
and 7600-fold (data not shown). However, the overall pat-
tern clearly indicated that IP-10 augmented the amount of
viral DNA detected following infection of MDM with HIV-
1BaL (five of seven donors) and in PBL infected by both
HIV-1BaL (three of four donors) and HIV-1BRU (four of
five). These data indicate that IP-10 stimulates HIV-1 rep-
lication largely by acting at a stage prior to viral transcrip-
tion.
IP-10 decreases C-C chemokine production and has no
effect on the surface expression of CD4, CCR5, or
CXCR4
Several previous studies have demonstrated that the che-
mokines MIP-1, MIP-1, and RANTES can inhibit HIV
entry into target cells (Cocchi et al., 1995; Coffey et al.,
1997). We therefore examined whether IP-10 might be
affecting viral entry by altering the expression of these
inhibitory chemokines. Supernatants from PHA-activated
PBL and MDM were collected after treatment with IP-10
and analyzed by ELISA for the presence of MIP-1, MIP-
1, and RANTES. In experiments with five different do-
nors’ PBL, decreased amounts of chemokines were detected
Table 1
Cellular viability is unaffected by treatment with IP-10
IP-10
(ng/ml)
MDM PBL
Donor 1 Donor 2 Donor 3 Donor 1 Donor 2 Donor 3
0 0.108 0.023 0.183  0.016 0.264  0.102 0.044  0.001 0.062  0.009 0.062  0.016
5 0.088 0.006 0.146  0.023 0.344  0.100 0.042  0.004 0.050  0.011 0.073  0.005
25 0.125 0.012 0.149  0.022 0.305  0.108 0.058  0.031 0.065  0.023 0.088  0.012
125 0.115 0.016 0.176  0.028 0.258  0.104 0.057  0.037 0.042  0.022 0.073  0.023
Note. Cellular viability, proliferation, and activation were assessed by using an MTT-based colorimetric assay according to the manufacturer’s instructions
(Boehringer Mannheim, Mannheim, Germany). The assay was performed on MDM 10 to 12 days after infection with HIV-1BaL and on PBL 9 days after
infection with HIV-1BRU. Data shown are the average value and standard deviation of absorbance values (A570–A650) for triplicate wells for each of three
donors. None of the differences were found to be significant by the Student’s t test.
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24 h after treatment with IP-10 (25 ng/ml). Compared with
untreated controls, MIP-1 levels were 89.9  6.3%;
MIP-1a´ levels were 79.9  29.4%, and RANTES levels
were 64.7  24.6%. These decreases were small but statis-
tically significant according to the Student’s t test for
MIP-1 (P  0.023) and RANTES (P  0.032), but can
only be called a trend for MIP-1 (P  0.20). Small de-
creases in MIP-1 and RANTES were also present in IP-
10-treated PBL that had been infected with either HIV-1BRU
or HIV-1BaL and cultured for up to 4 weeks. In three
independent experiments, significant decreases in MIP-1
(P  0.05) were found 4 weeks after infection with either
HIV-1BRU or HIV-1BaL. The level of MIP-1 in HIV-1BRU-
infected PBL treated with IP-10 was 50.6  20.0% of
untreated, HIV-1BRU-infected PBL. Similarly, the amount
of MIP-1 in IP-10-treated, HIV-1BaL-infected PBL was
67.3  12.6% of that from the supernatants of untreated,
HIV-1BaL-infected PBL. In contrast to the results with PBL,
IP-10 had no effect on MIP-1, MIP-1, and RANTES
production by MDM (data not shown).
HIV entry can also be modulated by the pattern and
levels of chemokine receptor expression (Kozak et al.,
1997; Littman, 1998; Wu et al., 1997). The increase in the
expression of the products of reverse transcription could be
explained by a positive effect of IP-10 on HIV-1 receptor
expression. We therefore examined whether treatment with
IP-10 affected the surface expression of CD4, CCR5, or
CXCR4 on peripheral blood monocytes (PBM) or PBL. We
found that the mean fluorescent intensity of CCR5, CXCR4,
and CD4 on PBL and PBM as measured by FACS analysis
is not changed by a 24-h treatment with IP-10 (data not
shown). In fact, the percentage of CCR5-expressing PBL
following IP-10 treatment is decreased to 72  11% of
untreated controls (n  3; P  0.05). Taken together, these
data indicate that the small decreases in the levels of MIP-
1, MIP-1, and RANTES may be at least partly respon-
sible for the effect of IP-10 on HIV-1 replication early in the
viral life cycle, but that alterations in the level of expression
of CD4, CCR5, or CXCR4 are unlikely to contribute.
Endogenous IP-10 and CXCR3 function to enhance HIV-1
replication in MDM
Having demonstrated that the addition of IP-10 stimu-
lates HIV-1 replication in primary human cells, we next
addressed whether endogenous CXCR3 and the CXCR3
ligands IP-10 and MIG are involved in HIV-1 replication as
well. Examination of PHA-activated PBL following infec-
tion with HIV-1 revealed a small amount of IP-10 (250
pg/ml) in the supernatants. MDM infected with viral stocks
prepared from PHA-activated PBL produced between 0.1
and 10 ng/ml of IP-10, in a manner largely dependent on
IFN- (data not shown). In contrast, MIG was undetectable
in the supernatants of unexposed and HIV-1-exposed PBL
and MDM (data not shown). Expression of I-TAC was not
examined, as we are not aware of any antibodies that cur-
rently exist for use in ELISA for this chemokine.
Although IP-10 has been studied mainly as a T cell
activator, it has also been shown to attract PBM (Luster and
Leder, 1993; Luster et al., 1985; Taub et al., 1993, 1996).
Even so, there has been some controversy in the literature
Fig. 2. IP-10 does not activate HIV-1 from latency in U1 cells. (A) The
chronically infected monocytic cell line U1 expresses CXCR3. Surface
receptors were analyzed by flow cytometric staining using a CXCR3-
specific monoclonal antibody, a CXCR4-specific monoclonal antibody as a
positive control, or mouse IgG as a negative control. Data shown are the
overlaid histograms for these three antibodies. The x-axis indicates the FL1
signal intensity (log FITC) and the y-axis indicates the number of events.
(B) IP-10 does not induce HIV-1 from latency in U1 cells. U1 cells were
left untreated or treated with PMA (16 nM) or IP-10 (25 ng/ml). Super-
natants were collected each day after infection for 4 days and analyzed for
RT activity. Data shown are from triplicate wells, and this experiment is
representative of three independent experiments.
126 B.R. Lane et al. / Virology 307 (2003) 122–134
about whether PBM express the IP-10 receptor CXCR3
(Loetscher et al., 1996). To determine whether endogenous
IP-10 (or MIG or I-TAC) might act through CXCR3 to
affect viral replication directly, we examined the expression
of CXCR3 in PBL and PBM by flow cytometry. We found
CXCR3 to be highly expressed on the cell surface of both
PBL and PBM (data not shown). Thus, we conclude that
signaling through CXCR3 has the potential to affect viral
replication in each of these cell types.
To assess whether endogenous IP-10 can stimulate
HIV-1 replication, as is the case with IL-8 and GRO-
(Lane et al., 2001a,b), we examined the effects of antibodies
that neutralize IP-10 and CXCR3 function on HIV-1 repli-
cation. An IP-10-specific monoclonal antibody and a
CXCR3-blocking antibody have previously been shown to
prevent the migration of T cells in response to IP-10 present
in cellular supernatants or added exogenously (Albanesi et
al., 2000; Jinquan et al., 2000). We used these same anti-
bodies to neutralize the activity of IP-10 in cultures of
HIV-1-infected PBL and MDM. Viral replication in both
PBL and MDM was inhibited by both anti-IP-10 and anti-
CXCR3 antibodies (Fig. 5). In PBL, anti-IP-10 had less of
an effect than that seen with anti-CXCR3 (Fig. 5A). This
may indicate that the other CXCR3 ligands are contributing
to HIV-1 replication in PBL, in agreement with our finding
that MIG and I-TAC also stimulate HIV-1 replication in
these same cells. In contrast, in HIV-1-infected MDM, in
which IP-10 is the dominant CXCR3 ligand present in
culture, treatment with either anti-IP-10 or anti-CXCR3
caused a significant reduction in HIV-1 replication (Figs. 5B
and 5C). Neither antibody substantially affected cellular
viability as determined by an MTT-based assay. Viability of
MDM treated with anti-IP-10 was 89%, and with anti-
CXCR3 was 84%, of untreated control cells in these six
experiments. We therefore conclude that endogenous IP-10
and CXCR3 play a stimulatory role in regard to HIV-1
replication in PBL and MDM.
Discussion
Cytokines play major roles in the pathogenesis of HIV
disease (Hogan and Hammer, 2001; Kinter et al., 2000;
Lahdevirta et al., 1988; Poli and Fauci, 1995). Chemokines,
in particular, have been shown to inhibit viral replication by
nature of their ability to compete with HIV-1 for binding to
its coreceptors, but also have stimulatory effects on viral
replication in certain settings. As evidence now indicates
that the ligands for the C-X-C chemokine receptors
CXCR1, CXCR2, and CXCR4 can all affect HIV-1 repli-
cation (Bleul et al., 1996; Lane et al., 2001a,b; Marechal et
Fig. 3. HIV-1 gene expression is not altered by IP-10 treatment in Jurkat T cells. (A) Jurkat cells were transfected with HIV-1 LTR-CAT (10 mg), with or
without RSV-Tat (1 g). Transfected cells were then split into separate wells and stimulated 16 h later with IP-10 (25 ng/ml), PMA (16 nM), or no further
treatment. CAT activity was evaluated 40 h after transfection. Data shown are representative of three independent experiments. (B) Jurkat cells stably
expressing HIV-1 LTR-luciferase (1G5) were treated with IP-10 (50 ng/ml), TNF- (50 ng/ml), or PMA (32 nM) for 48 h. Cell lysates were then analyzed
for luciferase activity. Data shown are the average of duplicate measurements and are representative of three independent experiments.
Table 2
IP-10 does not induce HIV-1-LTR-driven gene expression in PBL
Treatment Donor 1 Donor 2
None 2,699,360 222,176
PMA 45,587,392 14,842,304
IP-10 601,312 283,040
HIV-1 Tat 17,852,768 3,062,944
HIV-1 Tat  IP-10 9,080,160 269,336
Note. PBL were transfected with HIV-1 LTR-luc (20 g) with or
without RSV-Tat (2 g) by electroporation. Transfected PBL were then
split into separate wells and either left untreated, treated with IP-10 (50
ng/ml), or stimulated with PMA (32 nM). Luciferase activity present in
cellular lysates from two separate donors was measured 48 h after trans-
fection. Data are shown as counts per minute following subtraction of
background chemiluminescence.
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al., 1999; Oberlin et al., 1996), we evaluated the ability of
CXCR3 and its ligands to regulate HIV-1 replication.
While CXCR3 appears to function mainly on activated T
cells, several reports have indicated that IP-10 also attracts
PBM (Luster and Leder, 1993; Luster et al., 1985; Taub et
al., 1993, 1996). We have found expression of CXCR3 on
PBM as well as PBL and demonstrate here that IP-10
stimulates HIV-1 replication in both PBL and MDM and
appears to act at an early step in the viral life cycle. Treat-
ment with an IP-10-specific monoclonal antibody or a
blocking antibody to CXCR3 reduces HIV-1 replication in
MDM and PBL, demonstrating that endogenous IP-10 and
CXCR3 can stimulate HIV-1 replication in these primary
human cells.
We demonstrate here that IP-10, MIG, and I-TAC each
can stimulate HIV-1 replication in PBL and have chosen to
focus on IP-10 because of its greater relevance to HIV
disease in vivo. IP-10 is active in the range of 5 to 125
ng/ml, which is likely to be physiologically relevant, as CSF
levels of IP-10 up to 40 ng/ml have been detected in HIV-
infected individuals (Stylianou et al., 2000). While IP-10
levels in the plasma reach only 0.5 ng/ml in HIV-infected
individuals (Kolb et al., 1999), the amount of chemokine
available in the tissues where viral replication occurs is
likely to be much higher. PBMC and MDM have been
shown to produce up to 50 ng/ml of IP-10 in culture (Polu-
ektova et al., 2001; Wetzel et al., 2002). We found that
MDM produced significant amounts of IP-10, up to 10
ng/ml, in a manner dependent on IFN-. We found lower
levels of IP-10 in PBL cultures and no detectable MIG. The
fact that anti-IP-10 had some effect in PBL, and anti-
CXCR3 had a greater effect, suggests that endogenous I-
TAC may also be involved in the stimulation of HIV-1
replication in PBL. IP-10 has previously been implicated as
a downstream effector of IFN-mediated activity against
recombinant vaccinia viruses (Mahalingam et al., 1999). As
IP-10 production is induced by IFN-, IP-10 might act as a
mediator of some of the pathogenic actions ascribed to
IFN- in the context of HIV-1 infection (Cohen et al.,
1997). IFN- has long been known to inhibit HIV-1 repli-
cation in MDM and does so via decreasing CD4 expression
and viral entry (Dhawan et al., 1994, 1995). However,
IFN- has also been shown to enhance the expression of
several chemokine receptors, including CCR5, on mono-
cytic cell lines (Zella et al., 1998). In any case, the inhibi-
tory effects of IFN- on HIV-1 replication are not mediated
by IP-10, which we show in this article to increase viral
replication.
Several recent studies have shown that IP-10 plays a
significant role in the immune response to viral and proto-
Fig. 4. IP-10 and GRO- increase the accumulation of viral DNA in MDM and PBL. (A) MDM were treated with IP-10 or GRO- (each at 25 ng/ml) for
24 h prior to infection with HIV-1BaL. (B) Similarly, PHA-activated PBL were treated with IP-10 or GRO- (each at 25 ng/ml) for 24 h prior to infection
with HIV-1BRU. Cells were harvested at less than 24 h after infection and cell lysates were used in real-time quantitative PCR as described under Materials
and Methods. In these experiments, 10 to 1000 copies of viral DNA per 100,000 cells were detected in HIV-1-infected cells, while noninfected cells routinely
expressed1 copy of viral DNA per 100,000 cells. Data shown are the fold increase ( standard deviation) in viral DNA expression relative to the untreated,
HIV-1-infected cells. Shown in both panels are the mean values for all experiments in each of the two categories. IP-10 and GRO- stimulated viral DNA
accumulation in five of seven experiments with HIV-1BaL-infected MDM, three of four experiments with HIV-1BRU-infected PBL, and three of four
experiments with HIV-1BaL-infected PBL (not shown). The mean fold increases for IP-10 were 3.04, 3.75, and 13.6 for each of these experimental conditions,
respectively, and mean fold increases for GRO- were 4.62, 5.68, and 2.13.
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zoan infection (Amichay et al., 1996; Khan et al., 2000;
Mahalingam et al., 1999; Ramshaw et al., 1997). One report
indicates that IP-10 and MIG may participate in the host
defense against HIV-1 as well, as these CXCR3 ligands
contribute to the accumulation of HIV-specific cytotoxic T
lymphocytes in the lung (Agostini et al., 2000). IP-10 may
thus participate in the T cell mediated immune response to
HIV-1. Ultimately, these T cell mediated responses do not
usually control the spread of HIV-1, and so this action of
IP-10 may be less important than the HIV-enhancing role
we describe in this article. In addition, persistently elevated
IP-10 expression has been correlated with immunological
treatment failure following HAART (Stylianou et al., 2000),
so reducing IP-10 expression and function may enhance the
effectiveness of current anti-retroviral treatments.
Several lines of evidence suggest that treatments aimed
at inhibiting IP-10 function may have therapeutic benefit in
the context of HIV-1 infection. First, inhibition of IP-10
activity may decrease HIV-1 replication. We demonstrate
here that exogenous IP-10 stimulates HIV-1 replication in
PBL and MDM and that endogenous IP-10/CXCR3 signal-
ing contributes to HIV-1 replication in these same cells. The
mechanism by which IP-10 stimulates HIV-1 replication
appears to be distinct from the mechanisms employed by
other stimulatory factors, including TNF- and SDF-1.
TNF- is involved in a paracrine loop in which HIV-1
binding to CD4 induces TNF- production, and TNF-
stimulates HIV-1 gene expression by an NF-B-dependent
pathway (reviewed in Poli and Fauci, 1995). SDF-1 has
been shown to increase proviral gene expression by stimu-
lating the ability of Tat to transactivate the LTR (Marechal
et al., 1999). We have found that IP-10 does not affect
HIV-1 LTR-mediated gene expression, but rather increases
the accumulation of the products of reverse transcription in
both infected T cells and macrophages. Thus, IP-10 must act
at a step in the viral life cycle prior to viral transcription,
such as reverse transcription or, more likely, viral entry. IP-
10 decreases the production of MIP-1, MIP-1, and RAN-
TES, which may be at least partially responsible for the
increase in viral replication seen following treatment with
IP-10.
The chemokines RANTES, MIP-1, MIP-1, MCP-2,
and SDF-1 all have been shown previously to inhibit viral
entry by interfering with CCR5 or CXCR4 coreceptor func-
tion (Bleul et al., 1996; Cocchi et al., 1995; Gong et al.,
1998; Oberlin et al., 1996). As these chemokines exert
strong effects on viral entry, we hypothesized that IP-10
might also act on viral entry, perhaps by inducing changes
Fig. 5. Depletion of endogenous IP-10 or blocking CXCR3 inhibits HIV-1
replication in PBL and MDM. Cells were left untreated or treated with 20
mg/ml of either an isotype-matched control antibody (mouse IgG1), an
antibody that prevents interaction with CXCR3 (anti-CXCR3), or an anti-
body that neutralizes IP-10 activity (anti-IP-10) every 3 days, beginning 1
day before infection. Media was collected for the RT assay and replenished
twice weekly. (A) PBL were infected with HIV-1BRU. Data shown repre-
sent the average value of RT activity present in triplicate wells on days 3,
6, and 9 after infection. This experiment is representative of at least three
experiments with each antibody. (B) MDM were infected with HIV-1BaL.
The average values of RT activity from triplicate wells of a representative
experiment are shown over the course of infection. (C) RT data from six
independent experiments in which MDM were infected with HIV-1BaL are
presented. Data shown are normalized to the mouse IgG1 control on the day
of peak viral replication (mean  SEM). A significant reduction in HIV-1
replication relative to the no treatment and IgG control groups as deter-
mined by the Student’s t test was observed for treatment with anti-IP-10
(P  0.005, P  0.001), and for treatment with anti-CXCR3 (P  0.016,
P  0.035).
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in the expression of these chemokines or their receptors.
Our findings indicate that IP-10 reduces the amount of
MIP-1, MIP-1, and RANTES produced by activated
PBL. We found no significant change in surface expression
of CD4, CCR5, or CXCR4 in PBL or PBM, with only a
slight decrease in the percentage of CCR5-expressing PBL.
Thus, the effect of IP-10 on HIV-1 replication appears to be
mediated at least in part by decreases in the expression of
chemokines known to inhibit HIV-1 entry, but not by
changes in receptor expression.
IP-10 plays a role in HIV-associated brain disease. IP-10
and CXCR3 have been detected in the brain and CSF of
HIV-1-infected individuals (Kolb et al., 1999; Sanders et
al., 1998), and IP-10 is produced by astrocytes treated with
HIV-1 Tat and gp120 (Asensio et al., 2001; Kutsch et al.,
2000). Further, as cells of the monocytic lineage are the
major cell type infected with HIV-1 in the brain (Gartner,
2000; Gartner et al., 1986), monocytic cells produce IP-10,
and IP-10 stimulates HIV-1 replication within these cells,
inhibition of IP-10 activity may limit the brain pathology
associated with AIDS.
IP-10 is a potent chemotactic factor for both activated T
lymphocytes and PBM (Luster and Leder, 1993; Luster et
al., 1985; Taub et al., 1993, 1996). Preventing chemotaxis
of these cell types with inhibitors of IP-10 and CXCR3
function may reduce the spread of HIV-1 to uninfected
target cells (Swingler et al., 1999). Further, since IP-10 has
been demonstrated to function as the major T cell chemo-
tactic factor in the brain during HIV encephalopathy, reduc-
ing IP-10 activity may control T cell migration into the CNS
(Kolb et al., 1999).
In summary, we have demonstrated that IP-10 stimulates
HIV-1 replication by enhancing early steps in the viral life
cycle, likely including viral entry. We have also shown that
neutralization of endogenous IP-10 or blocking CXCR3
reduces HIV-1 replication in MDM and PBL. As IP-10 is
physiologically active in HIV-infected individuals both sys-
temically and in the CNS, interventions targeting IP-10 or
its receptor, CXCR3, may thus decrease HIV-1 replication
and the pathogenic effects seen with HIV-1 infection and
HIV-1-associated neurological disease.
Materials and Methods
Reagents
Recombinant human IP-10, MIG, and I-TAC, and mono-
clonal antibodies to human IP-10 (MAB266), were obtained
from R&D Systems (Minneapolis, MN) and added as indi-
cated in the figure legends. Cellular proliferation, viability,
and activation were assayed by using an MTT-based color-
imetric assay according to the manufacturer’s instructions
(Boehringer Mannheim, Mannheim, Germany). All other
chemicals were obtained from Sigma (St. Louis, MO).
Cell lines
The latently HIV-1-infected subclone of U937 promono-
cytic cells (U1), the latently HIV-1-infected lymphocytic
cell line ACH2, and a Jurkat cell line which contains a
stably integrated HIV-1 LTR-luciferase construct (1G5)
were obtained through the NIH AIDS Research and Refer-
ence Reagent Program. U1, ACH2, 1G5, and Jurkat cells
were each cultured in RPMI 1640 supplemented with 10%
FBS, 2 mM glutamine, 100 U/ml penicillin, and 100 g/ml
streptomycin (complete RPMI).
Isolation and preparation of PBMC, PBL, and PBM
Peripheral blood mononuclear cells were collected by
venipuncture of healthy volunteers as described previously
(Lane et al., 1999). PBMC contained approximately 20%
CD14 monocytes as determined by flow cytometry. To
separate the PBMC into subpopulations composed mainly
of monocytes or lymphocytes, PBMC were subjected to a
plate adherence step for 2 h. Adherent cells were consis-
tently 90% peripheral blood monocytes as determined by
Diff-Quik analysis and 85% CD14 by flow cytometric
staining with a PE-conjugated mouse anti-human monoclo-
nal antibody to CD14 (M5E2; PharMingen, San Diego,
CA), as well as 99% viable as determined by trypan blue
exclusion. PBM were differentiated into monocyte-derived
macrophages by culture in DMEM supplemented with 10%
FBS, 2 mM glutamine, 100 U/ml penicillin, and 100 g/ml
streptomycin (complete DMEM) for up to 2 weeks (3 days
in most experiments) prior to infection.
The nonadherent cells following the plate adherence step
were enriched for lymphocytes and contained less than 2%
CD14 monocytes. These monocyte-depleted PBMC
(PBL) were cultured at 1-2  106/ml in complete RPMI.
PBL were stimulated with 5 g/ml of phytohemagglutinin
(PHA; Sigma) for 1 to 3 days and then maintained in IL-2
(40 U/ml; Hoffmann-La Roche, Nutley, NJ). In some ex-
periments, PBL were also depleted of CD8 cells with
magnetic Dynabeads M-450 CD8 according to the manu-
facturer’s instructions (Dynal, Lake Success, NY).
Preparation of HIV-1 stocks
All of the HIV-1 isolates and infected cell lines used in
this article were originally obtained from the NIH AIDS
Research and Reference Reagent Program. Stocks of HIV-
1BaL were prepared by both infection of PHA-activated,
CD8-depleted PBL and infection of HOS-CD4-CCR5 cells.
Stocks of HIV-1BRU were prepared by infection of both
PHA-activated, CD8-depleted PBL and CEM-SS cells.
HIV-1 infection of MDM and PBL
For each experiment, multiple wells of MDM or PBL
were infected with equal RT counts of HIV-1 (30-300 
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106 CPM of RT used per 105 cells). This amount of CPM of
RT activity per cell corresponds to a multiplicity of infec-
tion (m.o.i.) of between 0.01 and 0.1 as determined by
titration on HOS-CD4-CCR5 and CEM-SS cell lines and
quantitation of proviral DNA in PBMC 24 h after infection
(data not shown). MDM were infected with HIV-1BaL for
16 h, washed, and then cultured in complete DMEM. PBL
were infected with HIV-1BRU for 4 h, washed, and then
incubated in complete RPMI IL-2. A portion of the media
(25%) was removed from the MDM and PBL cultures and
replaced twice weekly.
Reverse transcriptase assay
HIV-1 replication was determined by quantification of
the amount of RT activity present in the cellular superna-
tants at several points in time after infection using a
poly(A)-oligo(dT) template primer as previously described
(Potts et al., 1990). RT activity was assayed using 32P-
labeled deoxythymidine triphosphate incorporated in DNA
bound to DE81 paper (Whatman) and quantified using a
Series 400 PhosphorImager and ImageQuant software (Mo-
lecular Dynamics, Sunnyvale, CA). RT activity is reported
as PhosphorImager counts. The absolute values varied be-
tween experiments, but peak activity consistently occurred
4 to 7 days after infection of PBL and 7 to 14 days after
infection of MDM.
Transfection of Jurkat cells
Jurkat cells were transfected by the DEAE-dextran
method with 1 g HIV-1 Tat (pCG-Tat1) or control vector
(pCG) and 10 g of a plasmid containing the chloramphen-
icol acetyl transferase (CAT) reporter gene downstream of
the complete HIV-1 LTR. The cells were either left un-
treated or treated with IP-10 (25 ng/ml) or PMA (16 nM) at
16 h after transfection and harvested 40 h after transfection.
CAT activity was quantified and normalized for amount of
protein. Bars indicate the percentage conversion of chlor-
amphenicol to its acetylated form. Approximately 7000 cpm
of radioactivity were present in each sample.
Transfection of PBL
PBL were cultured in RPMI 1640 supplemented with
20% FBS, 1 g/ml PHA, 100 U/ml IL-2, 2 mM glutamine,
100 U/ml penicillin, and 100 g/ml streptomycin for 3 days.
PBL were washed in serum-free media and 12  106 cells
were transfected with 20 g of a luciferase reporter gene
under the control of the HIV-1 LTR (HIV-1 LTR-luc), and
in some instances along with 2 g HIV-1 Tat, in a volume
of 400 l. Cells were electroporated at 350 V in an Invitro-
gen (Carlsbad, CA) Electroporator II. Transfected cells
were then split into separate wells (4  106/well) and either
left untreated, stimulated with IP-10 (50 ng/ml), or stimu-
lated with PMA (32 nM). Cells were harvested at 48 h after
transfection. Cell lysates were collected and analyzed for
luciferase activity according to the manufacturer’s instruc-
tions (Promega, Madison, WI). Transfection yielded chemi-
luminescence readings 10- to 1000-fold above background,
which was 25,184 and 20,576 in the two experiments per-
formed.
ELISA
Cellular supernatants were collected after 19 to 48 h and
stored at 70°C until analysis. Extracellular immunoreac-
tive IP-10, MIG, MIP-1, MIP-1, and RANTES were
measured using a sandwich-type immunoassay (ELISA)
with capture and biotinylated detection antibodies according
to the manufacturer’s instructions (R&D Systems). The
lower limits of detection for these assays were between 13
and 32 pg/ml.
Flow cytometry
Cell staining was performed using monoclonal antibod-
ies to the human chemokine receptors CXCR2 (MAB331;
R&D Systems), CXCR3 (MAB160; R&D Systems), CCR5
(2D7; LeukoSite, Cambridge, MA), or CXCR4 (12G5;
PharMingen). PBMC or U1 cells were incubated in flow
buffer (HBSS  2% FBS  0.05% sodium azide) with
primary antibody for 30 min at 4°C. Cells were then washed
with flow buffer and incubated in flow buffer with the
secondary antibody (Biotin-conjugated goat anti-mouse
IgG; Jackson ImmunoResearch Laboratories) for 30 min at
4°C. Cells were then washed with flow buffer and incubated
in flow buffer with the staining reagent (fluorescein
(DTAF)-conjugated Streptavidin; Jackson ImmunoRe-
search Laboratories) for 30 min at 4°C. In some experi-
ments, cells were also stained with CyChrome-conjugated
anti-human CD4 (PharMingen) during the incubation with
DTAF-streptavidin. Background staining was determined
by adding an isotype-matched control antibody (mouse IgG)
during the first incubation. Cells were either analyzed im-
mediately or fixed in PBS  2% paraformaldehyde prior to
analysis. Cell staining analysis was performed using an XL
Z14107 cytometer. The PBL and PBM subpopulations were
gated according to the pattern of forward scatter and side
scatter and then analyzed for signal intensity in FL1. The
viable population of U1 cells was gated and analyzed for
FL1 signal intensity.
Real-time quantitative PCR for viral DNA
PBMC were collected by Ficoll–Hypaque density gradi-
ent centrifugation. PBM were adhered to plastic for 2 h, and
nonadherent cells (PBL) were collected. PBL were then
stimulated with PHA (5 g/ml) in complete RPMI for 2
days. PBL were washed and then cultured in complete
RPMI with IL-2 (40 U/ml) for two to four more days. PBL
(2 106/ml) were then treated overnight with the following
131B.R. Lane et al. / Virology 307 (2003) 122–134
chemokines at 25 ng/ml: IP-10, GRO-, or none. Equal RT
counts of HIV-1BRU or HIV-1BaL were added to PBL and
cells were spin-infected for 3 h at 2500 rpm. The media
were then replaced with fresh media containing the appro-
priate chemokine and IL-2. The next day, PBL were
counted and serial dilutions of PBL (1 to 100,000 cells)
were prepared. As a negative control, serial dilutions of
uninfected PBL were also collected. (These latter cells rou-
tinely contained 0 copies of viral DNA.) PBL were then
centrifuged, washed two times with PBS, and resuspended
in lysis solution. The samples were then incubated for 16 h
at 56°C and 4 h at 95°C and stored at 20°C until later use.
MDM were collected as described above and treated
overnight with IP-10, GRO-, or no chemokine prior to
infection with HIV-1BaL for 1 day. MDM were then treated
again with the appropriate chemokine, harvested, counted,
and lysed in the same manner as described for PBL.
The following primers and probe were used for real-time
quantitative PCR (numbering of nucleotide positions corre-
sponds to that for the HIV-1BRU DNA sequence): for LTR
U3/PBS: antisense primer (5	-CTT TCG CTT TCA AGT
CCC TGT T-3	; nucleotides 666-645 in the primer binding
site), sense primer (5	-CCC TCA GAT GCT GCA TAT
AAG CA-3	; nucleotides 9487 to 9509 in U3); probe, 5	-
FAM-CTC TCT GGT TAG ACC AGA TTT GAG CCT
GG-TAMRA-3	; nucleotides 458 to 486 in U5). PCR reac-
tion mixtures (50 l volume) were set up containing 5 l of
lysate, 5 mM MgCl2, 18 nM forward and reverse primer, 20
nM probe, 200 M of each deoxynucleotide triphosphate,
AmpErase UNG (0.5 l), and AmpliTaq DNA polymerase
(0.25 l). DNA was amplified as follows: 50°C for 2 min,
95°C for 10 min (1 cycle), 95°C for 15 s, 59°C for 1 min
(45-50 cycles), and 60°C for 1 min (1 cycle). The reaction
was performed with an ABI PRISM 7700 Sequence Detec-
tion System (PE Applied Biosystems, Foster City, CA), in
which the amount of PCR product can be assessed after
each cycle. The number of copies of viral DNA was quan-
titated by comparing unknowns to the data obtained with a
series of dilutions of a sample with known copy number (U1
or ACH2 cells) using Sequence Detector v1.6.3 software
(PE Applied Biosystems).
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